| This bioequivalence study demonstrates that the pharmacokinetic properties of a newly formulated extended-release oxycodone 10-mg tablet are bioequivalent to a marketed reference product under fasting and fed conditions. |
| Both treatments were well tolerated when taken without an opioid antagonist in healthy Japanese subjects. |
| Hydrophilic matrix technology is one of the proper methods to manufacture an oxycodone extended-release formulation. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.